1. scil Artisan Coral BioNet Scil Finance Holding GmbH Scil Technology Holding GmbH Scil Animal Care Scil Animal Care Scil Diagnostics Scil Diagnostics Scil Biomedicals Scil Biomedicals Scil Proteins Scil Proteins BioNet Laboratories Asia Diagnostics BioNet Laboratories Asia Diagnostics The SCIL Group Stefan Engelhorn 20 %80 %

2. scil Scil Technology Holding Use niches in Life Science to develop, manufacture and market innovative diagnostics and therapeutics Use investment possibilities to synergize the existing operative business Bridge the gap between VC funded companies and big pharma by using professional industrial development know how Create profit along the value chain for our partners and ourselves

3. scil Scil Technology Holding: Objectives Short term (3 years): Focus on industrial know how to develop and market products in diagnostics to generate short term cash flow. Partnerships with VC funded companies for co-development of innovative protein pharmaceuticals. Medium term (3 - 6 years): Project pipeline for innovative diagnostics and protein pharmaceuticals focussed on niche indications. Co-development and co-marketing of protein pharmaceuticals and innovative diagnostics products. Long term (> 6 years): Use the synergistic potential of diagnostic and therapeutic activities to create integrated solutions for more efficient treatments in niche indications

4. scil Scil Technology Holding: Competencies An one year old privately owned company which is actively involved in the development and marketing of diagnostics and therapeutics Diagnostics proprietary immunoassay technology and data transfer concept innovative reagent packaging concept sales organizations in Europe and Asia (Singapore) food testing products Therapeutics focus on the development of therapeutic proteins anti-L-selectin : prevention of polytrauma  clinical phase II immunotoxin MDX-RA : prevention of secondary cataract (partner Medarex)  clinical phase III bispec. antibody MDX-210: treatment of prostate cancer (partner Medarex)  clinical phase Ib Use the synergistic potential of diagnostics and therapeutics to create integrated health care concepts for niche indications

5. scil Scil Group: Management Team S. Engelhorn, Ph.D., M.D. G. Schumacher, Ph.D. J. Bornemann C. Dony, Ph.D. J. Feuerstein, Ph.D. R. Schenk, Ph.D. U. Martin, M.D. CEO of Scil Finance Holding. President of Scil Technology Holding. Member and chairman of several trusts CEO of Scil Technology Holding. 20 years of industrial experience in diagnostics and therapeutics. Former head of R&D at BM/Roche Vice President, CFO of Scil Technology Holding. Former at KPMG, tax consultant and commercial director at Gebr. März AG and Leonard Moll AG. Vice President, Research and Development of Scil Technology Holding. Former head of musculoskeletal disorders at BM/Roche, scientist at Genentech Inc. CEO of Scil Diagnostics. Former global strategic project planning at BM/ Roche. Focus: marketing, PSO organization management, partnership management CEO of Scil Diagnostics. Former head of system development and leader project lab diagnostics at BM/Roche. Focus: system and technology concepts and implementation CEO of Scil Pharmaceuticals. Former head of pharmacology and cardiovascular research at BM/Roche and senior scientist at Hoechst

6. scil Scil Biomedicals: Mission Scil Biomedicals is a young privately owned company with the mission to use professional industrial drug-development know how to develop, manufacture and market innovative bio-pharmaceuticals

7. scil Scil Biomedicals: Corporate Profile  Founded in May 1999  Privately owned company  Subsidiary of Scil Technology Holding GmbH  Focus: development of protein pharmaceuticals; innovative products for niche indications - specific treatments for cancer and inflammation - tissue regeneration: ophthalmic, bone and cartilage

8. scil Scil BioMedicals: Facilities and people Location in Martinsried/ Munich Employees: 10 people (20 people by mid of 2000) 700 square ft. lab space, Gründerzentrum Martinsried 9000 square ft. lab- and office-space (3/2000)

9. scil Scil Biomedicals : Core Management Team CEO U. Martin former head of pharmacology and cardiovascular research at BM/Roche; senior scientist at Hoechst Pre-clinical Research C. Dony Biotechnology U. Kohnert Pharmaceutical Sciences R. Seidl Non-clinical Development U. Martin Clinical Development M. Beckert Former head of musculoskeletal disorders R&D at BM/Roche; scientist at Genentech project leader biotechnology for reteplase, specialist in preformulation at BM/Roche Former head of pharmacology, project leader: therap. Mab`s, gene therapy at BM/Roche Former head of clinical research at MSD Team of legal (B. Jurisch), patent (B. Huber) and diagnostic (A. Wahlefeld) advisors Project leader quality control at Mucos pharma

10. scil Scil Biomedicals: Core Competence Development of protein pharmaceuticals from active compound to approval

11. scil Scil Biomedicals: Core Competence Development of protein pharmaceuticals Protein bulk drug Finished product  Integrated technology platform for bulk drug and finished product - protein process development - formulation/drug delivery - pharmaceutical analyses Pre-clinic bioanalytics Clinical development Regulatory affairs  Experienced steering of non-clinical and clinical development activities including GMP manufacturing via CROs  Team of project leaders with experience in inter- national project development and regulatory filing (FDA & EMEA for RapiLysin ® /Retavase TM ) Approval

12. scil Scil Biomedicals: Fast track development of Anti-L-Selectin (BNP 001) in 1999 Anti-L-selectin for the prevention of multi organ failure (partner: PDL) after polytrauma January 15 February 24 March 31 June 2 June 4 July 14 July 28 November LETTER OF INTENT: PDL - BioNet for anti-L-selectin Start TECHNICAL TRANSFER (know how, reports and materials) CONTRACT PDL - BioNet signed CLINICAL DRUG SUPPLIES released PHASE I: first in man DOSE SELECTION FOR PHASE II Submission of phase II study protocol to CENTRAL ETHICS COMMITTEE of PI PHASE II (Polytrauma): “first patient in”

13. scil Scil Biomedicals: Strategic Focus Development of innovative protein pharmaceuticals Antibodies and growth factors as specific therapies for niche indications  Oncology, (tumor specific therapies)  Inflammation (multi organ failure)  Eye disorders  bone and cartilage disorders

14. scil Scil Biomedicals: Research & Development Pipeline Immunotoxin MDX-RA  prevention of secondary cataract (partner Medarex) - clinical phase III - market entry 2003 Anti-L-selectin  prevention of multi organ failure after severe polytrauma (partner: PDL) - clinical phase II - market entry 2003/4 Bispecific antibody MDX-210  late stage prostate cancer (partner Medarex) - clinical phase Ib - market entry 2005 research on growth factors for tissue regeneration eg. bone and cartilage disorders

15. scil Scil Proteins is a young privately owned company with the mission to use professional scientific and industrial protein production know how to develop and manufacture pharmaceutical proteins Scil Proteins: Mission

16. scil Development of pharmaceutical proteins from design to production of an active protein Scil Proteins: Core competence

17. scil Scil Proteins: Core technologies Technologies/Services: Small scale production of recombinant proteins Refolding of E. coli inclusion body proteins samples for: preclinical research protein structure analysis rationale drug design Protein binding Molecule Technology

18. scil Scil Proteins: Core competence Development of pharmaceutical proteins Recombinant protein production  Pro- and eukaryotic expression systems  Fermentation 10l, 50l, 100l reactors  Refolding of proteins frominclusion bodies  Proteinpurification conventional methods, affinity techniques  Physicochemical characterization CD, fluorescence, mass spectroscopy, biacore Customized protein folding Isolation of stable binding proteins  Screening of scaffold phage display libraries

19. scil Scil Proteins: Facilities and people Scil Proteins: People and facilities Location in Halle/Saale Scientific founder Prof. R. Rudolph, Inst. of Biotechnology, Halle Employees: 6 people (12 people by end of 2000) 1000 square foot lab- and office-space associated with the Institute for Biotechnology (3/2000) 4200 square foot lab- and office-space “Gründerzentrum Halle” (10/2000)

20. scil Scil Protein Technology Services: Core Competence Expression systems (pro- and eukaryotic organisms) Fermentation facilities: 10 l-, 50 l-, 100 l-reactors (E. coli) Highly specialized protein refolding technology - automatic protein folding reactor for proteins expressed in inclusion bodies (E. coli) Proteinpurification: conventional methods and affinity techniques to guarantee straight forward purification of protein samples Physicochemical characterized and proteinprofiling, mass spectroscopy, CD, fluorescence/biacore, protein sequencing, etc.

21. scil Scil Protein Technology Services Projects of the Institute of Protein Technologies: Prof. R. Rudolph, Halle Successful refolding of inclusion body proteins expressed in E. coli Protein GLP1-Receptor pro NGF pro BMP2 PTH-Receptor Proteinase K Enterokinase Pepsinogen Procollagen C Proteinase h Phosphodiesterase PDE 4 HIV Protease Antibody fragments CD 4 Helicase Partnership Boehringer Mannheim Roche Genetics Institute Schweizer Rotes Kreuz / Novartis Pfizer University Leipzig / AWD University Halle -